Endometrium karsinomu ve prekanseröz lezyonları arasında immunohistokimyasal olarak glipikan3, GLUT1, galektin3 ve GATA3 ekspresyonlarının karşılaştırılması
Yükleniyor...
Dosyalar
Tarih
2015
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Düzce Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Bu çalışmadaki amaç; bir çok dokuda hücresel matürasyonda görevli, neoplastik transformasyonda suçlanan ve maligniteler ile beraber ekspresyonu saptanan Glipikan3, GLUT1, Galektin3 ve GATA3 moleküllerinin endometrium karsinomu ve hiperplazilerinde ekspresyonlarını araştırmak ve prognostik faktörler ile ilişkisini incelemektir. Gereç ve Yöntem: Düzce Üniversitesi Tıp Fakültesi Patoloji Anabilim Dalı'nda 2010-2014 yılları arasında endometrial karsinom ve endometrial hiperplazi tanısı almış vakalar arasından parafin bloklarına ulaşılabilen 22 adet histerektomi ve 85 adet endometrial küretaj materyali çalışmaya alındı. H&E kesitleri tekrar değerlendirildi ve uygun bir blok seçilerek glipikan3, GLUT1, galektin3 ve GATA3 antikoru ile immünohistokimyasal çalışma yapıldı. Sonuçlar olguların patoloji raporlarında bulunan hasta yaşı, tümör derecesi, myometrium invazyon derinliği, lenfovasküler invazyonu ve tümör evresi gibi prognostik kriterler ile karşılaştırıldı. Bulgular: Çalışmamızda glipikan3 endometrioid karsinom olgularında hiperplazi ve normal endometriuma göre daha fazla boyanma gösterdi. Ayrıca tümör derecesi arttıkça glipikan3 yoğunluğunun da arttığı gözlendi (p=<0,05). Yüksek derece endometrial karsinomlar galektin3 ile nükleer boyanma gösterirken, tümör derecesi arttıkça stromal galektin3 boyanmasının azaldığı gözlendi. Endometrioid karsinom ve atipili hiperplazi olgularında, atipisiz hiperplazi olgularına göre daha fazla GLUT1 boyanması saptandı. Ki67 indeksi ile GLUT1 arasında pozitif yönlü korelasyon mevcuttu (r=0,25,p=0,008). Tanı grupları arasında yalnızca endometrioid karsinom ile atipik hiperplazi olguları GATA3 boyanması gösterdi ve boyanma yoğunluğu birbirine oldukça yakındı (sırasıyla %9,5, %5,0). Sonuçlar: Endometrial lezyonlarda karsinom-hiperplazi ayırıcı tanısında glipikan3 immunreaksiyonun gösterilmesi endometrial karsinom lehine kuvvetli bir bulgudur ve endometrial karsinomda prognostik bir faktör olarak kullanılabilir. Endometrial karsinom olgularında galektin3 çok değişik paternde boyanma gösterebilmektedir. Galektin3'ün, epitelyal-stromal ve sitoplazmik-nükleer boyanması ayrı ayrı değerlendirilerek patoloji raporunda bulunması faydalı bir prognostik faktör olacaktır. GLUT1 atipili-atipisiz hiperplazilerin ayrımında kullanılabilecek faydalı bir antikordur. Patoloji raporunda GLUT1 yoğunluğu hakkında bilgi verilmesi klinik ve radyoloji için yararlı olacaktır. GATA3'ün endometrial karsinom-hiperplazi ayırıcı tanısında kullanılmasının yararı yoktur. Endometrial karsinomda ise GATA3 kaybı tümörün derecesini artıran bir faktördür. ANAHTAR SÖZCÜKLER, Endometrioid Karsinom, GLUT1, Galektin3, Glypican3, GATA3
Aim: Glypican3, Galectin3, GLUT1 and GATA3 have been shown to function in cellular maturation, neoplastic transformation, tumor progression and in metastatic spread. The aim of this study was to investigate the relationship between Glypican3, Galectin3, GLUT1 and GATA3 expression and clinicopathologic factors in endometrial carcinoma and hyperplasias. Materials and Methods: The studied materials were obtained from the archieve of Medical Faculty of Düzce University between 2010- 2014. The materials comprised samples of 22 TAH and 85 endometrial curettage which have been diagnosed as endometrial carcinoma and endometrial hyperplasia. The diagnosis is confirmed on H&E sections. Immunohistochemical analysis with Glypican3, Galectin3, GLUT1 and GATA3 was performed. The data regarding the clinical and pathological characteristics of the patients was obtained from the medical records. Results: The percentage of Glypican3 expression was found to be significantly higher in endometrioid carcinomas when compared to endometrial hyperplasia and normal endometrium. The Gylpican 3 staining was increased with increasing tumor grade (p=<0.05). In high grade endometrioid carcinomas, galectin3 immunostaining was detected in the nuclei. Decreased stromal staining of galectin3 was observed, while increasing tumor grade . Endometrioid carcinoma and atypical endometrial hyperplasias were shown to be more related to higher GLUT1 immunostaining than non-atypical hyperplasias. There was a correlation between ki67 index and GLUT1 (r=0,25,p=0,008). Only endometrioid carcinoma and atypical endometrial hyperplasias were shown to have GATA3 expression. The percentage of staining was similar to each other (9,5%, 5,0%). Conclusion: Glypcan3 expression is a strong evidence for endometrial carcinoma in differential diagnosis of carcinoma and hyperplasias and can be used as a prognostic factor. Expression of galectin3 in endometrioid carcinoma was observed in heterogeneous pattern. We suggested that evaluating galectin3 in tumor cells according to the combination models such as epithelial-stromal and cytoplasmic-nuclear in pathology report serves as a prognostic factor GLUT1 expression has value in differential diagnosis of atypical-nonatypical hyperplasias. We considered reporting intensity of GLUT1 would also be useful for clinical practice and radiology. There is no benefit of GATA3 expression in differentiating endometrial carcinoma and hyperplasia. Loss of GATA3 is found to be related to the results in increased tumor grade in endometrial carcinoma. KEYWORDS, Endometrioid Carcinoma, GLUT1, Galectin3, Glypican3, GATA3
Aim: Glypican3, Galectin3, GLUT1 and GATA3 have been shown to function in cellular maturation, neoplastic transformation, tumor progression and in metastatic spread. The aim of this study was to investigate the relationship between Glypican3, Galectin3, GLUT1 and GATA3 expression and clinicopathologic factors in endometrial carcinoma and hyperplasias. Materials and Methods: The studied materials were obtained from the archieve of Medical Faculty of Düzce University between 2010- 2014. The materials comprised samples of 22 TAH and 85 endometrial curettage which have been diagnosed as endometrial carcinoma and endometrial hyperplasia. The diagnosis is confirmed on H&E sections. Immunohistochemical analysis with Glypican3, Galectin3, GLUT1 and GATA3 was performed. The data regarding the clinical and pathological characteristics of the patients was obtained from the medical records. Results: The percentage of Glypican3 expression was found to be significantly higher in endometrioid carcinomas when compared to endometrial hyperplasia and normal endometrium. The Gylpican 3 staining was increased with increasing tumor grade (p=<0.05). In high grade endometrioid carcinomas, galectin3 immunostaining was detected in the nuclei. Decreased stromal staining of galectin3 was observed, while increasing tumor grade . Endometrioid carcinoma and atypical endometrial hyperplasias were shown to be more related to higher GLUT1 immunostaining than non-atypical hyperplasias. There was a correlation between ki67 index and GLUT1 (r=0,25,p=0,008). Only endometrioid carcinoma and atypical endometrial hyperplasias were shown to have GATA3 expression. The percentage of staining was similar to each other (9,5%, 5,0%). Conclusion: Glypcan3 expression is a strong evidence for endometrial carcinoma in differential diagnosis of carcinoma and hyperplasias and can be used as a prognostic factor. Expression of galectin3 in endometrioid carcinoma was observed in heterogeneous pattern. We suggested that evaluating galectin3 in tumor cells according to the combination models such as epithelial-stromal and cytoplasmic-nuclear in pathology report serves as a prognostic factor GLUT1 expression has value in differential diagnosis of atypical-nonatypical hyperplasias. We considered reporting intensity of GLUT1 would also be useful for clinical practice and radiology. There is no benefit of GATA3 expression in differentiating endometrial carcinoma and hyperplasia. Loss of GATA3 is found to be related to the results in increased tumor grade in endometrial carcinoma. KEYWORDS, Endometrioid Carcinoma, GLUT1, Galectin3, Glypican3, GATA3
Açıklama
YÖK Tez No: 424617
Anahtar Kelimeler
Patoloji, Pathology, Endometrial neoplazmlar, Endometrial neoplasms, GLUT-1, GLUT-1, Galektin-3, Galectin-3, Glipikan 3, Glypican 3, Karsinoma, Carcinoma, Neoplazmlar, Neoplasms, Prekanseröz durumlar, Precancerous conditions, İmmünohistokimya, Immunohistochemistry
